Mar 27, 2025 8:05am EDT Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation
Mar 04, 2025 4:01pm EST Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Feb 25, 2025 8:05am EST Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update
Jan 22, 2025 8:05am EST Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease
Dec 09, 2024 12:02pm EST Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition
Dec 02, 2024 8:05am EST Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS
